Published • loading... • Updated
‘Game Changer’ Drug Turns Cancer’s Defenses Against Itself
The phase one trial of RSO-021 was well tolerated, and researchers said patients lived longer than those given standard treatments.
- A UVM study published on July 14 in Nature Communications reports that an experimental drug inhibited PRX3 to control relapsed mesothelioma in 67% of patients in a phase one trial sponsored by RS Oncology, LLC.
- Mesothelioma tumors rely on PRX3, an antioxidant enzyme in mitochondria, to survive oxidative stress. Researchers developed a treatment to inhibit this enzyme, overwhelming tumor cells and triggering their death.
- In a phase one trial of 15 patients conducted in the United Kingdom, the drug proved well-tolerated and patients lived longer than those given standard treatments, with some tumors shrinking.
- Phase two of the drug trial has now been completed, with results expected to be presented at a global oncology meeting later this year, potentially expanding applications to other cancers.
- Efforts are underway to develop second-generation PRX3 inhibitors with improved solubility and bioavailability. Researchers believe this mechanism could be applicable to cancer types beyond mesothelioma.
Insights by Ground AI
33 Articles
33 Articles
Study reports a counterintuitive new approach to treating mesothelioma
Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year.
·United States
Read Full Article
New cancer drug demonstrates potential in mesothelioma clinical trial
A groundbreaking study from the University of Vermont has revealed a novel approach to treating mesothelioma, a deadly cancer caused by asbestos exposure, offering new hope to patients with limited options. Traditionally, mesothelioma treatment relies on immunotherapy and chemotherapy, which provide only modest survival benefits and often leave patients with a median survival of just […]
Coverage Details
Total News Sources33
Leaning Left6Leaning Right8Center16Last UpdatedBias Distribution53% Center
Bias Distribution
- 53% of the sources are Center
53% Center
L 20%
C 53%
R 27%
Factuality
To view factuality data please Upgrade to Premium
